| Literature DB >> 34943643 |
Annamária Kincses1, Bálint Rácz1, Zain Baaity1, Orsolya Vásárhelyi1, Erzsébet Kristóf1, Ferenc Somogyvári1, Gabriella Spengler1.
Abstract
Urinary tract infections (UTIs) are common bacterial infections caused mainly by enteric bacteria. Numerous virulence factors assist bacteria in the colonization of the bladder. Bacterial efflux pumps also contribute to bacterial communication and to biofilm formation. In this study, the phenotypic and genetic antibiotic resistance of clinical UTI pathogens such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis were determined by disk diffusion method and polymerase chain reaction (PCR). Following this, different classes of antibiotics were evaluated for their antibacterial activity at pH 5, 6, 7 and 8 by a microdilution method. Gentamicin (GEN) was the most potent antibacterial agent against E. coli strains. The effect of GEN on the relative expression of marR and sdiA genes was evaluated by quantitative PCR. The slightly acidic pH (pH 6) and GEN treatment induced the upregulation of marR antibiotic resistance and sdiA QS activator genes in both E. coli strains. Consequently, bacteria had become more susceptible to GEN. It can be concluded that antibiotic activity is pH dependent and so the artificial manipulation of urinary pH can contribute to a more effective therapy of multidrug resistant bacterial infections.Entities:
Keywords: biofilm; efflux pump; multidrug resistance; pH dependence; quorum sensing; urinary tract infection (UTI)
Year: 2021 PMID: 34943643 PMCID: PMC8697967 DOI: 10.3390/antibiotics10121431
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Phenotypic antibacterial susceptibility results.
| Antibiotic | ||||||
|---|---|---|---|---|---|---|
| Ampicillin | 22 mm S | 25 mm S | 6 mm R | 0 mm R | 0 mm R | 0 mm R |
| AMC | 22 mm S | 25 mm S | 23 mm S | 8 mm R | 28 mm S | 0 mm R |
| Cefuroxime | 22 mm S | 25 mm S | 20 mm S | 0 mm R | 28 mm S | 0 mm R |
| Ceftriaxone | 30 mm S | 34 mm S | 24 mm S | 8 mm R | 30 mm S | 15 mm R |
| Ceftazidime | 27 mm S | 30 mm S | 24 mm S | 8 mm R | 30 mm S | 8 mm R |
| CZA | 26 mm S | 28 mm S | 24 mm S | 24 mm S | 30 mm S | 28 mm S |
| TMP/SMX | 0 mm R | 30 mm S | 18 mm S | 0 mm R | 0 mm R | 0 mm R |
| Ertapenem | 35 mm S | 35 mm S | 30 mm S | 30 mm S | 30 mm S | 30 mm S |
| Imipenem | 30 mm S | 30 mm S | 30 mm S | 30 mm S | 30 mm S | 30 mm S |
| Meropenem | 30 mm S | 30 mm S | 30 mm S | 30 mm S | 30 mm S | 30 mm S |
| Gentamicin | 13 mm R | 22 mm S | 20 mm S | 0 mm R | 24 mm S | 15 mm R |
| Tobramycin | 20 mm S | 22 mm S | 20 mm S | 15 mm I | 24 mm S | 14 mm R |
| Amikacin | 20 mm S | 22 mm S | 20 mm S | 25 mm I | 24 mm S | 22 mm I |
| Ciprofloxacin | 0 mm R | 30 mm S | 16 mm R | 0 mm R | 35 mm S | 0 mm R |
| Norfloxacin | 0 mm R | 30 mm S | 16 mm R | 0 mm R | 35 mm S | 0 mm R |
AMC: amoxicillin-clavulanic acid, TMP/SMX: Trimethoprim Sulfamethoxazole (sumetrolim), CZA: Ceftazidime/Avibactam.
ESBL, quinolone, and sulfonamide resistance genes in UTI bacterial isolates.
| Resistance Type | Gene |
|
|
| |||
|---|---|---|---|---|---|---|---|
| 32313 | 33504 | 32470 | 33877 | 33163 | 33443 | ||
| ESBL |
| − | − | + | − | + | + |
|
| − | − | + | + | − | − | |
|
| − | − | + | − | − | − | |
|
| − | − | + | − | − | − | |
| Fluoroquinolones |
| − | − | − | − | − | − |
|
| − | − | − | − | − | − | |
|
| − | − | − | − | − | − | |
|
| − | − | − | − | − | − | |
|
| − | − | + | + | + | + | |
|
| + | − | + | − | + | − | |
|
| − | − | − | − | − | − | |
|
| − | − | − | − | − | − | |
| Resistance type |
| − | − | − | − | − | − |
|
| + | − | + | + | + | + | |
|
| − | − | − | + | − | − | |
Minimal inhibitory concentrations for erythromycin, ampicillin, ciprofloxacin and gentamicin on E. coli, K. pneumoniae and P. mirabilis strains.
| MIC (µg/mL) | Erythromycin | Ampicillin | Ciprofloxacin | Gentamicin | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pH | pH | pH | pH | |||||||||||||
| 5 | 6 | 7 | 8 | 5 | 6 | 7 | 8 | 5 | 6 | 7 | 8 | 5 | 6 | 7 | 8 | |
| >100 | >100 | 12.5 | 3.125 | 12.5 | 12.5 | 12.5 | 25 | 3.125 | 0.39 | 0.05 | <0.05 | 25 | 6.25 | 1.56 | 0.05 | |
| >100 | >100 | >100 | >100 | >25 | >25 | >25 | >25 | >25 | >25 | 25 | >25 | 25 | 12.5 | 1.56 | 1.56 | |
| >100 | >100 | 25 | 12.5 | >25 | >25 | >25 | >25 | 25 | 6.25 | 0.78 | 0.19 | 25 | 6.25 | 0.78 | <0.05 | |
| >100 | >100 | >100 | 25 | >25 | >25 | >25 | >25 | >25 | >25 | >25 | 12.5 | >25 | >25 | >25 | 12.5 | |
| >100 | >100 | >100 | 50 | >25 | >25 | >25 | >25 | 0.78 | <0.05 | <0.05 | <0.05 | >25 | >25 | 6.25 | 0.39 | |
| >100 | >100 | 100 | 25 | >25 | >25 | >25 | >25 | >25 | >25 | >25 | >25 | >25 | >25 | 12.5 | 3.125 | |
Figure 1Relative gene expression levels of marR and sdiA genes in the presence of gentamicin in Escherichia coli 32313 after 8 h exposure. The line denotes the threshold value, which was set at a two-fold increase in transcripts.
Figure 2Relative gene expression levels of marR and sdiA genes in the presence of gentamicin in Escherichia coli 33504 after 8 h exposure. The line denotes the threshold value, which was set at a two-fold increase in transcripts.
ESBL resistance genes and primers.
| Gene | Primer | Sequence (5′-3′) | Amplicon Size (bp) | Reference |
|---|---|---|---|---|
|
| F | 800 | [ | |
| R | CGTTCATCCATAGTTGCCTG | |||
|
| F | AGCCGCTTGAGCAAATTAA | 713 | |
| R | ||||
|
| F | GGCACCAGATTCAACTTTCA | 564 | |
| R | GACCCCAAGTTTCCTGTAAG | |||
|
| F | TTTGCGATGTGCAGTACC | 544 | [ |
| R | CGATATCGTTGGTGGTGC |
Plasmid-mediated quinolone resistance genes and primers [24].
| Gene | Primer | Sequence (5′-3′) | Amplicon Size (bp) |
|---|---|---|---|
|
| F | CAGCAAGAGGATTTCTCACG | 630 |
| R | |||
|
| F | CGAGATCAATTTACGGGGAATA | 581 |
| R | |||
|
| F | GGCTGTCAGTTCTATGATCG | 488 |
| R | |||
| degR | SAKCAACGATGCCTGGTAG | ||
|
| F | GCAAGTTCATTGAACAGGGT | 428 |
| R | TCTAAACCGTCGAGTTCGG | ||
|
| F | CCGCACCGATAAATTAGTCC | 313 |
| R | GGCGAGGTTTTGATAGTGG | ||
|
| F | TTGGAAGCGGGGACG | 260 |
| R | ACACGGCTGGACCATA | ||
|
| F | 218 | |
| R | |||
|
| F | GCAGAATTCAGGGGTGTG | 118 |
| R | AACTGCTCCAAAAGCTGC |
Sulfonamide resistance genes and primers [26].
| Gene | Primer | Sequence (5′-3′) | Amplicon Size (bp) |
|---|---|---|---|
|
| qF | TGTCGAACCTTCAAAAGCTG | 113 |
| qR | TGGACCCAGATCCTTTACAG | ||
|
| qF | ATCTGCCAAACTCGTCGTTA | 89 |
| qR | CAATGTGATCCATGATGTCG | ||
|
| qF | GGTTGAAGATGGAGCAGATG | 111 |
| qR | GCCTTAATGACAGGTTTGAGTC |
Forward and reverse primers used for the assessment of the activity of the multiple antibiotic resistance regulator gene marR and the quorum-sensing regulator sdiA of Escherichia coli 33504 and 32313.
| Gene | Primer | Sequence (5′-3′) | Amplicon Size (bp) | Reference |
|---|---|---|---|---|
|
| F | AGCGATCTGTTCAATGAAAT | 170 | [ |
| R | TTCAGTTCAACCGGAGTAAT | |||
|
| F | CTGATGGCTCTGATGCGTTTA | 163 | [ |
| R | TCTGGTGGAAATTGACCGTATT | |||
|
| F | ACTTACGAGCAGATCAAAGC | 170 | [ |